Copyright
©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Feb 15, 2026; 17(2): 112475
Published online Feb 15, 2026. doi: 10.4239/wjd.v17.i2.112475
Published online Feb 15, 2026. doi: 10.4239/wjd.v17.i2.112475
Fibroblast growth factor 1 alleviates diabetic nephropathy by reducing renal lipid accumulation in diabetic kidney
Ying-Jian Li, Yin-Li Huang, Xiao-Qing Yan, Department of Endocrinology, Pingyang Hospital of Wenzhou Medical University, Wenzhou 325499, Zhejiang Province, China
Ying-Jian Li, He-Yu Ge, Gui-Gui Zhang, Hao-Yu Chen, Yu-Jia Xi, Xiao-Qing Yan, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, Zhejiang Province, China
Kai Wang, Department of Cardiology, Heart Center, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
Chi Zhang, Wenzhou Key Laboratory for The Diagnosis and Prevention of Diabetic Complications, The Third Affiliated Hospital of Wenzhou Medical University (Ruian People’s Hospital), Wenzhou 325200, Zhejiang Province, China
Xia Fan, School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou 325027, Zhejiang Province, China
Co-first authors: Ying-Jian Li and He-Yu Ge.
Co-corresponding authors: Xia Fan and Xiao-Qing Yan.
Author contributions: Li YJ and Ge HY had equal contribution to the present research as co-first authors; Li YJ, Ge HY and Zhang GG performed in vivo experiments in mice; Li YJ, Ge HY, Zhang GG, Chen HY, Xi YJ, Wang K and Huang YL performed in vitro cell culture, cell biology, molecular biology experiments, and histology analysis; Li YJ and Yan XQ wrote the manuscript; Zhang C and Fan X edited the manuscript with important intellectual content; Fan X and Yan XQ supervised this study and equally contributed to the present research as co-corresponding authors; all authors have read and approved the final version to be published.
Supported by National Natural Science Foundation of China, No. 82470453 and No. 82370832; Natural Science Foundation of Zhejiang Province, No. LY22H020005; and The Summit Advancement Disciplines of Zhejiang Province (Wenzhou Medical University-Pharmaceutics).
Institutional animal care and use committee statement: All animal experiments were carried out in accordance with the procedures and guidelines of the institutional animal ethics committee for animal experiments and approved by the Laboratory Animal Ethics Committee of Wenzhou Medical University, Wenzhou, Zhejiang Province, China, No. wydw2021-0643.
Conflict-of-interest statement: The authors declare no conflicts of interest.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: The data presented in this study are available on request from the corresponding author.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Qing Yan, PhD, Associate Professor, School of Pharmaceutical Sciences, Wenzhou Medical University, University-Town, Wenzhou 325035, Zhejiang Pro
Received: July 28, 2025
Revised: October 12, 2025
Accepted: November 27, 2025
Published online: February 15, 2026
Processing time: 193 Days and 4.2 Hours
Revised: October 12, 2025
Accepted: November 27, 2025
Published online: February 15, 2026
Processing time: 193 Days and 4.2 Hours
Core Tip
Core Tip: Fibroblast growth factor 1 (FGF1) can effectively ameliorate diabetic nephropathy as reflected by improved renal function and alleviation of kidney morphological abnormalities. FGF1 alleviates renal lipid accumulation, as evidenced by decreased triglyceride content and repressed adipose differentiation-related protein expression, via inhibiting fatty acid uptake and promoting lipid catabolism in diabetic kidney. Mechanical studies demonstrated that FGF1 modulates renal lipid metabolism via restoring AMP-activated protein kinase activity and peroxisome proliferator-activated receptor alpha expression.